

Edgar Filing: AcuNetx, Inc. - Form 10QSB

AcuNetx, Inc.
Form 10QSB
August 21, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

Form 10-QSB

(X) Quarterly Report under Section 13 or 15(d) of the Securities Exchange
Act of 1934 for the quarterly period ended June 30, 2006

Commission File No. 0-27857

AcuNetx, Inc.

(Exact name of small business issuer as specified in its charter)

Nevada

88-0249812

(State or other jurisdiction
of incorporation or organization)

(I.R.S. Employer
Identification No.)

1000 S. McCaslin, Suite 300, Superior, CO 80027

(Address of principal executive offices)

303-494-1681

(Issuer's telephone number)

Check whether the issuer: (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file for such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No []

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [] No [X]

As of June 30, 2006 the issuer had 57,199,814 shares of common stock outstanding.

Transitional Small Business Disclosure Format (check one) [] Yes; [X] No

CAUTIONARY NOTICE REGARDING FORWARD LOOKING STATEMENTS

This Report on Form 10-QSB contains a number of forward-looking statements that reflect management's current views and expectations with respect to our business, strategies, products, future results and events and financial performance. All statements made in this Report other than statements of historical fact, including statements that address operating performance, events or developments that management expects or anticipates will or may occur in the future, including statements related to distributor channels, volume growth, revenues, profitability, new products, acquisitions, adequacy of funds from operations, statements expressing general optimism about future operating results and non-historical information, are forward-looking statements. In

Edgar Filing: AcuNetx, Inc. - Form 10QSB

particular, the words "BELIEVE," "EXPECT," "INTEND," "ANTICIPATE," "ESTIMATE," "MAY," "WILL," variations of such words, and similar expressions identify forward-looking statements, but are not the exclusive means of identifying such statements and their absence does not mean that the statement is not forward-looking. These forward-looking statements are subject to certain risks and uncertainties, including those discussed below. Our actual results, performance or achievements could differ materially from historical results as well as those expressed in, anticipated or implied by these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Readers should not place undue reliance on these forward-looking statements, which are based on management's current expectations and projections about future events, are not guarantees of future performance, are subject to risks, uncertainties and assumptions (including those described below) and apply only as of the date of this Report. Our actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below "Management's Discussion and Analysis and Plan of Operation," as well as those discussed elsewhere in this Report, and the risks discussed in our most recently filed Annual Report on Form 10-KSB and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors that may affect our business.

2

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

ACUNETX, INC. (F/K/A EYE DYNAMICS, INC.) CONSOLIDATED BALANCE SHEET (UNAUDITED)

	JUNE 30, 2006

ASSETS	
Current Assets	
Cash	\$ 99,491
Accounts receivable, net	124,408
Inventory	340,160
Prepaid expenses	129,721

Total Current Assets	693,780
Property and equipment, net	31,282
Goodwill	4,823,500
Other intangible assets	117,133
Deferred tax assets	220,635
Other investment	158,595
Other assets	1,563
TOTAL ASSETS	\$ 6,046,488

Edgar Filing: AcuNetx, Inc. - Form 10QSB

LIABILITIES AND STOCKHOLDERS' EQUITY	
Current Liabilities	
Accounts payable	\$ 401,147
Accrued liabilities	126,119
Notes payable, current portion	161,309

Total Current Liabilities	688,575
Long-Term Debt	82,422

Total Liabilities	770,997

Stockholders' Equity	
Common stock, \$0.001 par value; 100,000,000 shares authorized; 57,199,814 shares issued and outstanding	57,200
Paid-in capital	9,911,859
Accumulated deficit	(4,693,568)

Total Stockholders' Equity	5,275,491

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$ 6,046,488
	=====

See Notes to Interim Unaudited Consolidated Financial Statements

3

ACUNETX, INC. (F/K/A EYE DYNAMICS, INC.)
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

	FOR THREE MONTHS ENDED JUNE 30,		
	2006	2005	2006
-----	-----	-----	-----
Sales - Products	\$ 371,730	\$ 402,785	\$ 655,
Cost of Products	148,675	187,283	269,
	-----	-----	-----
Gross profit	223,055	215,502	385,
	-----	-----	-----
Operating Expenses:			
Selling, general and administrative expenses	1,141,583	174,581	1,969,
Stock option expenses	136,846	--	244,
Research and development	146,022	--	191,
	-----	-----	-----
Total Operating Expenses	1,424,451	174,581	2,405,
	-----	-----	-----

Edgar Filing: AcuNetx, Inc. - Form 10QSB

Operating income (loss)	(1,201,396)	40,921	(2,019,
Other income (expenses)			
Interest and other income	11,021	128	16,
Loss on equity-method investments	(10,804)	--	(28,
Interest expense	(8,445)	(194)	(19,
Total other income (expenses)	(8,228)	(66)	(31,
Net income (loss) before taxes	(1,209,624)	40,855	(2,050,
Provision for income taxes	--	1,276	1,
Net income (loss)	\$ (1,209,624)	\$ 39,579	\$ (2,052,
Net income (loss) per share-basic	\$ (0.02)	\$ 0.00	\$ (0
Net income (loss) per share-diluted	\$ (0.02)	\$ 0.00	\$ (0
Shares used in per share calculation-basic	56,918,605	21,674,880	55,389,
Shares used in per share calculation-diluted	56,918,605	22,179,707	55,389,
Shares used in per share calculation-basic	56,918,605	21,674,880	55,389,
Shares used in per share calculation-diluted	56,918,605	22,179,707	55,389,

See Notes to Interim Unaudited Consolidated Financial Statements

4

ACUNETX, INC. (F/K/A EYE DYNAMICS, INC.)
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

FOR SIX MONTHS ENDED JUNE 30,	2006	2005
CASH FLOW FROM OPERATING ACTIVITIES:		
Net loss	\$ (2,052,154)	\$ (35,881)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation	6,297	80
Issuance of stocks and stock equity awards for services	577,178	68,000
Provision for bad debt	6,512	--
Provision for loan loss	--	9,116
Deferred income tax	366	1,276
Loss on investment accounted for under equity method	28,690	--
(Increase) Decrease in:		
Accounts Receivable	(14,821)	(112,841)
Inventory	(18,900)	(83,292)
Prepaid and Others	(40,318)	24,725
Increase (Decrease) in:		
Accounts Payable and Accrued Liabilities	162,562	19,150

Edgar Filing: AcuNetx, Inc. - Form 10QSB

NET CASH USED IN OPERATING ACTIVITIES	(1,344,588)	(109,667)
CASH FLOW FROM INVESTING ACTIVITIES:		
Closing of Certificate of Deposits	305,274	--
Capitalize of patent costs	(20,945)	--
Capitalize of trademark	(6,567)	--
Purchase of Equipment	(5,283)	--
Repayment from Notes Receivable	--	1,500
Purchase of Certificate of Deposits	--	(400,000)
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	272,479	(398,500)
CASH FLOW FROM FINANCING ACTIVITIES:		
Net proceeds from sale of common stocks	1,036,529	--
Net proceeds from exercising of stock warrants	20,000	--
Repayments on notes payable	(56,269)	--
NET CASH PROVIDED BY FINANCING ACTIVITIES	1,000,260	--
NET DECREASE IN CASH	(71,849)	(508,167)
CASH BALANCE AT BEGINNING OF PERIOD	171,340	847,235
CASH BALANCE AT END OF PERIOD	\$ 99,491	\$ 339,068
Supplemental Disclosures of Cash Flow Information:		
Interest Paid	\$ 19,069	\$ --
Taxes Paid	\$ 800	\$ 800
Schedule of noncash investing and financing activities:		
Issuance of common stocks for:		
Merger adjustment	\$ 362	\$ --
Notes Payable	--	40,000
Accrued Interest	--	6,339
	\$ 362	\$ 46,339

See Notes to Interim Unaudited Consolidated Financial Statements

NOTE 1 - NATURE OF BUSINESS

AcuNetx, Inc., a Nevada corporation, (the "Company" or "AcuNetx", formerly known as Eye Dynamics, Inc. or "EDI") combines diagnostic, analytical and therapeutic devices with proprietary software to permit: health providers to diagnose and treat balance disorders and various bone deficiencies; to allow law enforcement officers to evaluate roadside sobriety; and permits employers in high-risk industries to determine, in real-time, the mental fitness of their employees to perform mission-critical tasks. AcuNetx is headquartered in Superior Colorado, and has operating divisions in Torrance, California.

Edgar Filing: AcuNetx, Inc. - Form 10QSB

On December 23, 2005, the Company completed a merger with OrthoNetx, Inc. ("OrthoNetx" or "ONX"), a Colorado-based provider of medical devices for osteoplastic surgery. The acquisition was completed as a stock transaction in which ONX shareholders received shares of the merged company equal to the number of EDI's outstanding shares at the closing date. Following the merger, the Company changed its name to AcuNetx, Inc. and shifted its headquarters to Superior, Colorado. The President and CEO of ONX assumed the position of President and CEO of the merged company.

AcuNetx is organized around three separate divisions: (i) a division that produces neurological diagnostic equipment, (ii) a division that produces devices that create new bone, and (iii) a division that develops products for occupational safety and law enforcement. For all its devices, AcuNetx is in the process of integrating an information technology (IT) platform that allows the device to capture data about the physiological condition of a human being. The Company's IT platform is designed to gather data and connect the device-related data with users and support personnel. Its products include the following: (a) neurological diagnostic equipment that measures, tracks and records human eye movements, utilizing our proprietary technology and computer software, as a method to diagnose problems of the vestibular (balance) system and other balance disorders; (b) devices designed to test individuals for impaired performance resulting from the influences of alcohol, drugs, illness, stress and other factors that affect eye and pupil performance, targeted toward the occupational safety and law enforcement markets; (c) orthopedic and craniomaxillofacial (skull and jaw) surgery products, which generate new bone through the process of distraction osteogenesis; and (d) a proprietary information technology system called SmartDevice-Connect(TM) ("SDC") that establishes product registry to individual patients and tracks device behavior for post-market surveillance, adverse event and outcomes reporting, and creates "smart devices" that gather and transmit physiological data concerning the device and its interaction with the patient.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

PRESENTATION OF INTERIM INFORMATION: The financial information at June 30, 2006 and for the three and six months ended June 30, 2006 and 2005 is unaudited but includes all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial information set forth herein, in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information, and with the instructions to Form 10-QSB. Accordingly, such information does not include all of the information and footnotes required by U.S. GAAP for annual financial statements. For further information refer to the Consolidated Financial Statements and footnotes thereto included in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2005.

The results for the three and six months ended June 30, 2006 may not be indicative of results for the year ending December 31, 2006 or any future periods.

PRINCIPLE OF CONSOLIDATION AND PRESENTATION: The accompanying financial statements include the accounts of AcuNetx, Inc. and its divisions after elimination of all intercompany accounts and transactions. Certain prior period balances have been reclassified to conform to the current period presentation.

USE OF ESTIMATES: The preparation of the accompanying consolidated financial statements in conformity with accounting principles generally accepted in the United States (U.S. GAAP) requires management to make certain estimates and assumptions that directly affect the results of reported assets, liabilities, revenue, and expenses. Actual results may differ from these estimates.

Edgar Filing: AcuNetx, Inc. - Form 10QSB

OTHER INTANGIBLE ASSETS: Other intangible assets consist primarily of intellectual property and trademarks. The Company capitalizes intellectual property costs as incurred, excluding costs associated with Company personnel, relating to patenting its technology. The majority of capitalized costs represent legal fees related to a patent application. If the Company elects to stop pursuing a particular patent application or determines that a patent application is not likely to be awarded or elects to discontinue payment of required maintenance fees for a particular patent, the Company, at that time, records as expense the capitalized amount of such patent application or patent. Awarded patents will be amortized over the shorter of the economic or legal life of the patent. Trademarks are not amortized, but rather are tested for impairment at least annually. There was no impairment of other intangible assets for six months ended June 30, 2006. The Company had no other intangible assets in 2005.

6

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

GOODWILL: Goodwill represents the excess of the purchase price in the merger with OrthoNetx (see Note 10 below) over the fair value of net tangible and intangible assets acquired in the merger. Goodwill amounts are not amortized, but rather are tested for impairment at least annually. There was no impairment of goodwill for six months ended June 30, 2006. The Company had no goodwill in 2005.

INVESTMENT: The Company held 20% of the issued and outstanding common stock of a Colorado privately-held company. The Company accounts for the investment using the equity method of accounting. Under the equity method, the carrying amount of the investment is increased for its proportionate share of the investee's earning or decreased for its proportionate share of the investee's loss. During the six month period ended June 30, 2006, the Company recorded losses of \$28,690, as its pro rata share of net losses in this privately-held company. The Company had no equity method investment in 2005.

The Company monitors the investment for impairment and makes appropriate reductions in carrying value if the Company determines that an impairment charge is required based primarily on the financial condition and near-term prospects of this company.

INCOME (LOSS) PER COMMON SHARE: Basic net income (loss) per share includes no dilution and is computed by dividing net income (loss) available to common stockholders by the weighted average number of common stock outstanding for the period. Diluted earnings per share is computed by dividing net income by the weighted average number of shares outstanding and, when, diluted, potential shares from options and warrants to purchase common stock using the treasury stock method. Diluted net loss per common share does not differ from basic net loss per common share since potential shares of common stock are anti-dilutive for all periods presented.

STOCK-BASED COMPENSATION: Prior to January 1, 2006, the Company's stock option plans were accounted for under the recognition and measurement provisions of APB Opinion No. 25 (Opinion 25), "ACCOUNTING FOR STOCK ISSUED TO Employees," and related Interpretations, as permitted by FASB Statement No. 123, "ACCOUNTING FOR STOCK-BASED COMPENSATION" (as amended by SFAS No. 148, "ACCOUNTING FOR STOCK-BASED COMPENSATION TRANSITION AND DISCLOSURE") (collectively SFAS 123). No stock-based employee compensation cost was recognized in the Company's consolidated statements of operations through December 31, 2005, as all options granted under the plans had an exercise price equal to the market value of the

Edgar Filing: AcuNetx, Inc. - Form 10QSB

underlying common stock on the date of grant. Effective January 1, 2006, the Company adopted the fair value recognition provisions of FASB Statement No. 123(R), "SHARE-BASED PAYMENT" (SFAS 123R), using the modified-prospective-transition method. Under that transition method, compensation cost recognized in 2006 includes: (a) compensation cost for all share-based payments granted prior to, but not yet vested as of January 1, 2006 based on the grant date fair value calculated in accordance with the original provisions of SFAS 123, and (b) compensation cost for all share-based payments granted subsequent to December 31, 2005, based on the grant-date fair value estimated in accordance with the provisions of SFAS 123(R).

For the three and six months ended June 30, 2006, as a result of adopting SFAS 123(R) on January 1, 2006, the Company recognized pre-tax compensation expense related to stock options of \$136,846 and \$244,876, respectively. The following table illustrates the effect on net loss and net loss per share if the Company had applied the fair value recognition provisions of SFAS 123 to options granted under the Company's stock option plan for the three and six months ended June 30, 2005. For purposes of this pro forma disclosure, the value of the options is estimated using the Black-Scholes option-pricing model and is being amortized to expense over the options' vesting periods.

	Three Months ended June 30, 2005 -----	Six Months ended June 30, 2005 -----
Net income (loss), as reported	\$ 39,579	\$ (35,881)
Deduct: Total stock-based employee compensation expense determined under the fair value of awards, net of tax related effects	-- -----	39,600 -----
Pro forma net income (loss)	\$ 39,579 =====	\$ (75,481) =====
Reported net income (loss) per share-basic and diluted	\$ 0.00 =====	\$ (0.00) =====
Pro forma net income (loss) per share-basic and diluted	\$ 0.00 =====	\$ (0.01) =====

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

The Company accounts for stock issued to non-employees in accordance with the provisions of SFAS No. 123 and the EITF Issue No. 00-18, "ACCOUNTING FOR EQUITY INSTRUMENTS THAT ARE ISSUED TO OTHER THAN EMPLOYEES FOR ACQUIRING, OR IN CONJUNCTION WITH SELLING, GOODS OR SERVICES." SFAS No. 123 states that equity instruments that are issued in exchange for the receipt of goods or services should be measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Under the guidance in Issue 00-18, the measurement date occurs as of the earlier of (a) the date at which a performance commitment is reached or (b) absent a performance commitment, the date at which the performance necessary to earn the equity instruments is complete (that is, the vesting date).

NEW ACCOUNTING PRONOUNCEMENTS: In June 2006, the Financial Accounting Standards

Edgar Filing: AcuNetx, Inc. - Form 10QSB

Board (FASB) issued Interpretation No. 48, "ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES", ("FIN 48"). This Interpretation clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements in accordance with FASB Statement No. 109, "ACCOUNTING FOR INCOME TAXES." This Interpretation prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. This Interpretation also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. FIN 48 is effective for fiscal years beginning after December 15, 2006. The Company does not expect the adoption of FIN 48 to have a material impact on its consolidated financial statements.

The FASB has also issued Statements of Financial Accounting Standards (SFAS) No. 155, "ACCOUNTING FOR CERTAIN HYBRID FINANCIAL INSTRUMENTS-AN AMENDMENT OF FASB STATEMENTS NO. 133 AND 140" and SFAS No. 156, "ACCOUNTING FOR SERVICING OF FINANCIAL ASSETS-AN AMENDMENT OF FASB STATEMENT NO. 140" but they will not have a relationship to the operations of the Company. Therefore a description and its impact for each on the Company's operations and financial position have not been disclosed.

NOTE 3 - BALANCE SHEET DETAILS

The following tables provide details of selected balance sheet items:

As of June 30, 2006

ACCOUNTS RECEIVABLE, NET

Accounts Receivable	\$ 128,985
Other Receivable	57
Allowance for Bad Debt	(4,634)

Total Accounts Receivable, Net	\$ 124,408
=====	

PREPAID EXPENSES AND OTHERS

Prepaid Insurance	\$ 30,637
Prepaid rent and deposit	7,210
Other Prepaid Expenses	91,874

Total Prepaids and Others	\$ 129,721
=====	

PROPERTY AND EQUIPMENT, NET

Furniture and Fixtures	\$ 9,531
Equipment	48,945
Software	6,285

	64,761
Accumulated Depreciation	(33,479)

Total Property and Equipment, Net	\$ 31,282
=====	

ACCRUED LIABILITIES

Accrued insurance	\$ 5,723
Warranty reserve	8,462
Accrued payroll and related taxes	59,375
Accrued consulting fees	19,090
Accrued vacation	27,602

Edgar Filing: AcuNetx, Inc. - Form 10QSB

Other accrued liabilities	5,867

Total Accrued Liabilities	\$ 126,119
	=====

8

NOTE 4 - LONG-TERM DEBT

The Company has a note payable to a related party which initially bears interest at 0.75% above the Wall Street Journal Prime Rate (8.0% at December 31, 2005) and matures on January 10, 2006. On January 17, 2006, the note agreement was amended to reflect that the payment date of the loan be extended for two years, that the interest rate be increased to 13% per annum and that the remaining principal balance be amortized and payable over 2 years. The note is collateralized by substantially all assets of the Company and personal guarantee by the CEO and two shareholders. As of June 30, 2006, the balance of the note payable is \$243,731, including a current portion of \$161,309. Total interest expense for the six months ended June 30, 2006 was \$19,065.

In April 2005, the Company converted notes payable of \$40,000 and accrued interest of \$6,339 into 3,591,799 shares of common stock pursuant to the conversion privileges stated in the original note agreements. As a result, the Company did not recognize any gain or loss from these conversions.

NOTE 5 - INCOME TAXES

The components of the deferred net tax assets are as follows:

		For Three Months ended June 30,		For Six Months ended June 30,	
		2006	2005	2006	2005

Federal:					
Current	\$	--	\$ --	\$ --	\$ --
Deferred		--	1,276	377	1,276

		--	1,276	377	1,276

State:					
Current		--	--	800	800
Deferred		--	--	(11)	--

		--	--	789	800

Total	\$	--	\$ 1,276	\$ 1,166	\$ 2,076
=====					

The Company had removed the valuation allowance as of December 31, 2003 because it believed it was more likely than not that all deferred tax assets would be realized in the foreseeable future and was reflected as a credit to operations. However, as of December 31, 2005, the Company's ability to utilize its federal net operating loss carryforwards is uncertain due to the net loss of the year and the merger with OrthoNetx which has net operating loss carryforwards approximately of \$1.7 million as of that date, and thus a valuation reserve has been provided against the Company's net deferred tax assets.

As of December 31, 2005, the Company has net operating loss carryforwards of approximately \$3,200,000 and \$833,000 to reduce future federal and state taxable

Edgar Filing: AcuNetx, Inc. - Form 10QSB

income, respectively. To the extent not utilized, the federal net operating loss carryforwards will begin to expire in fiscal 2009 and the state net operating loss carryforwards will begin to expire in fiscal 2012.

NOTE 6 - STOCKHOLDERS' EQUITY

Private Placement Offering

In September 2005, OrthoNetx commenced a private placement offering ("Offering") of equity securities to raise on a best efforts basis a maximum of \$1,500,000 in conjunction with the planned merger with Eye Dynamics discussed in Note 3. There is no minimum amount required to be raised with the Offering. The Offering consists of units priced at \$50,000 per unit. Each unit consists of (a) shares of the OrthoNetx's common stock at a price equal to the lesser of \$.22 per share or 90% of the average closing price of Eye Dynamics common stock over the 30 days prior to the closing of the merger with Eye Dynamics and (b) warrants to purchase additional shares of the OrthoNetx's common stock equal to 50% of the number of shares of common stock purchased in the Offering, exercisable for two years at \$.33 per share. Total proceeds from this offering were \$650,000; the Company received net proceeds of \$602,779 after offering expenses. Additional offering expenses of \$81,250 were paid, of which \$15,000 was paid in cash in 2005; \$16,250 was paid in cash in 2006; and the balance of \$50,000 was paid in 277,778 shares of AcuNetx's common stock. All cash proceeds were received in January 2006 and total of 3,888,892 shares of AcuNetx's common stock, including the 277,778 shares, were issued.

9

NOTE 6 - STOCKHOLDERS' EQUITY (CONTINUED)

In March 2006, a Subscription Agreement from the 2005 Private Placement Memorandum was fulfilled in the amount of \$500,000, resulting in \$450,000 net proceeds after offering expenses. Galen Capital Group, the former financial advisor, is the investor and received 2,777,778 shares of common stock of the Company for its investment.

Exercise of stock warrants

During the first six months of 2006, there were stock warrants exercised. The Company received total proceeds of \$20,000. No stock warrants were exercised in 2005.

Non-Executive Directors' Stock Plan

On February 27, 2006 the Board of Directors agreed to provide 300,000 shares of restricted stock to each of the four nonemployee directors as compensation for 2006 services pursuant to the 2006 Non-Executive Stock Plan established on January 1, 2006. The shares were ratified valuing at \$0.18 per share which was the closing market price on the effective date of the Plan, and were amortized on a straight-line basis over a twelve month period. For the three and six months ended June 30, 2006, the Company recognized directors' compensation of \$28,500 and \$103,500. The Plan shall be in effect until December 31, 2006.

Increase of Authorized Shares

Edgar Filing: AcuNetx, Inc. - Form 10QSB

In March 2006, the Board of Directors approved to increase the number of authorized common stocks to 200 million. Increase in authorized common shares requires shareholder approval, which will be sought at the next shareholder meeting. If approved at that time, the Articles of Incorporation will be amended.

NOTE 7 - STANDBY EQUITY DISTRIBUTION AGREEMENT

On January 31, 2006, the Company entered into a Standby Equity Distribution Agreement (SEDA) with Cornell Capital Partners, LP ("Cornell"), to finance the continued development of its products. Under the agreement, Cornell has committed to provide up to \$12 million of equity financing to be drawn down over a 24-month period at the Company's discretion. The financing will become available after the Company has filed a Registration Statement covering the securities with the Securities and Exchange Commission (the "SEC"), and the SEC has declared the Registration Statement effective. The maximum amount of each drawdown is \$500,000, and there must be at least five trading days between drawdowns.

Under the Standby Equity Distribution Agreement, each drawdown is actually a sale by the Company to Cornell of newly-issued shares of common stock, in the amount necessary to equate to the desired cash proceeds. Cornell will pay the Company 98% of, or a 2% discount to, the lowest closing bid price of the Company's common stock during the five consecutive trading day period immediately following the date the Company notifies Cornell that the Company desires to access the Standby Equity Distribution Agreement. Under the agreement, the Company may not issue Cornell a number of shares of common stock such that it would beneficially own greater than 9.99% of the Company's outstanding shares of common stock.

In addition, Cornell Capital Partners will retain 5% of each cash payment under the Standby Equity Distribution Agreement as a commitment fee. The Company also issued, as amended, 1,090,266 shares of common stock to Cornell Capital Partners as a one-time commitment fee. The 2% discount, the 5% commitment fee and the shares of common stock are considered to be underwriting discounts payable to Cornell Capital Partners. The Company also paid \$5,000 as a due diligence fee to Cornell Capital Partners.

The Company also agreed to pay Yorkville Advisors, LLC, an affiliate of Cornell Capital Partners, a structuring fee of \$10,000 upon the earlier to occur of (i) the first drawdown under the Standby Equity Distribution Agreement, or (ii) April 21, 2006, as well as a fee of \$500 per advance made.

Under the agreement, the Company has issued three warrants to purchase the Company's common stock to Cornell. The first is a one-year warrant for 250,000 shares, with an exercise price of \$0.50 per share. The second is a two-year warrant for 250,000 shares, with an exercise price of \$1.00 per share. The third is a three year warrant for 500,000 shares, with an exercise price of \$2.00 per share. The warrants were valued at \$83,802 using Black-Scholes option-pricing model and were charged to operations.

NOTE 7 - STANDBY EQUITY DISTRIBUTION AGREEMENT (CONTINUED)

The Company agreed to register for resale, on Form SB-2, the shares of common stock which the Company sell to Cornell Capital Partners under the Standby Equity Distribution Agreement, as well as shares issuable upon exercise of the warrants and the shares issued as a commitment fee.

Edgar Filing: AcuNetx, Inc. - Form 10QSB

The Company engaged Monitor Capital, Inc., a registered broker-dealer, to act as placement agent in connection with the Standby Equity Distribution Agreement, pursuant to a Placement Agent Agreement dated as of January 31, 2006. The Company paid Monitor Capital, Inc. 57,143 shares of Common Stock as a fee under the Placement Agent Agreement. The shares were valued at \$0.175 per share. The total of \$10,000 was charged to operations.

NOTE 8 - STOCK OPTIONS

On March 27, 2006 the Board of Directors approved and adopted the 2006 Stock Incentive Plan to provide for the issuance of incentive stock options and/or nonstatutory options to all employees and nonstatutory options to consultants and other service providers. Generally, all options granted to employees and consultants expire ten and three years, respectively, from the date of grant. All options have an exercise price higher than the fair market value of the Company's stock on the date the options were granted. It is the policy of the Company to issue new shares for stock option exercised and restricted stock, rather than issue treasury shares. Options generally vest over three years. The plan reserves 14 million shares of common stock under the Plan and shall be effective through December 31, 2015.

On January 3, 2005, the Board of Directors approved to issue stock options to directors in the amount of 20,000 shares for each of the years from 1999 through 2004. The total options for each of directors shall be 120,000 shares. The options are vesting immediately and exercisable at \$0.15 per share through January 3, 2007.

A summary of the status of stock options issued by the Company as of June 30, 2006 and 2005 is presented in the following table.

	2006		2005	
	Number of Shares	Weighted Average Exercise Price	Number of Shares	Weighted Average Exercise Price
Outstanding at beginning of year	415,000	\$ 0.15	--	\$ --
Granted	6,894,102	0.21	360,000	0.15
Exercised/Expired/Cancelled	--	--	--	--
Outstanding at end of period	7,309,102	\$ 0.21	360,000	\$ 0.15
Exercisable at end of period	1,301,602	\$ 0.19	360,000	\$ 0.15

The fair value of each stock option granted is estimated on the date of grant using the Binominal Lattice option valuation model for 2006 and the Black-Scholes Merton option valuation model for 2005. Both models use the assumptions listed in the table below. Expected volatilities are based on the historical volatility of the Company's stock. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury yield curve in effect at the time of grant.

	2006	2005
Weighted average fair value per option granted	\$ 0.17	\$ 0.11

Edgar Filing: AcuNetx, Inc. - Form 10QSB

Risk-free interest rate	4.41%	3.18%
Expected dividend yield	0.00%	0.00%
Expected lives	9.80	2.00
Expected volatility	155.69%	163.36%

As of June 30, 2006 there was \$896,097 of total unrecognized compensation cost related to nonvested share-based compensation arrangements granted under the various plans. That cost is expected to be recognized over a weighted average period of 2.5 years.

11

NOTE 9 - NET INCOME (LOSS) PER SHARE

The following table sets forth the computation of basic and diluted net income (loss) per share:

	Three Months ended June 30, 2006	2005	Six 20
Basic net income (loss) per share:			
Net income (loss)	\$ (1,209,624)	\$ 39,579	\$ (2,0
Weighted average number of common shares	56,918,605	21,674,880	55,3
Basic net income (loss) per common share	\$ (0.02)	\$ 0.00	\$
Diluted net income (loss) per share:			
Net income (loss)	\$ (1,209,624)	\$ 39,579	\$ (2,0
Addback: Debenture interest	--	--	--
Adjusted net income (loss)	\$ (1,209,624)	\$ 39,579	\$ (2,0
Weighted average number of common shares	56,918,605	21,674,880	55,3
Incremental shares from assumed conversion:			
Convertible debt	--	--	--
Stock options and warrants	--	504,827	--
Adjusted weighted average number of common shares	56,918,605	22,179,707	55,3
Diluted net income (loss) per common share	\$ (0.02)	\$ 0.00	\$

As the Company incurred net loss for the three and six months ended June 30, 2006, the effect of dilutive securities totaling 693,537 and 693,407 equivalent shares, respectively, have been excluded from the calculation of diluted loss per share because their effect was anti-dilutive.

As the Company incurred net loss for the six months ended June 30, 2005, the effect of dilutive securities totaling 513,333 equivalent common shares have been excluded from the calculation of diluted net loss per share because their effect was anti-dilutive.

NOTE 10 - MERGERS AND ACQUISITIONS

Edgar Filing: AcuNetx, Inc. - Form 10QSB

Pursuant to the Agreement and Plan of Merger ("ONX Agreement") with OrthoNetx, Inc., a privately-held company in Colorado, dated September 1, 2005, the Company acquired 100% of the issued and outstanding common stock of OrthoNetx. The acquisition was completed on December 23, 2005.

OrthoNetx, Inc., which was formed in 1996, develops, manufactures, markets and supports proprietary medical devices for distraction osteogenesis (mechanically induced growth of new bone and adjacent soft tissues) to treat human bone-related tissue deficiencies and deformities, both congenital and acquired. OrthoNetx has patented and developed its GENEROS(TM) family of distraction osteogenesis devices for infants, children and adults with: (a) craniofacial deformities and mandibular, maxillary and/or alveo (dental) bone loss, and (b) deficiencies and malformations of the upper and lower limbs, and in the bones of hands and feet.

Under the terms of the ONX Agreement, the shareholders of ONX received the number of shares equal to the number of outstanding shares of EDI's common stock, including stock options and stock warrants at the closing date. As a result, each outstanding share of ONX's common stock was converted into approximately 0.805 shares of AcuNetx's common stock. Immediately upon the completion of the merger, ONX's CEO became the CEO of AcuNetx.

12

NOTE 10 - MERGERS AND ACQUISITIONS (CONTINUED)

The acquisition was accounted for as business combination, and accordingly, the tangible assets acquired were recorded at their fair value at December 23, 2005. The results of operations of OrthoNetx have been included in the Company's consolidated financial statements subsequent to that date. The total purchase price is \$4,706,061, and is comprised of:

Stocks issued to acquire the outstanding common stock of OrthoNetx (22,496,966 shares at \$0.18 per share)	\$4,049,454
Acquisition related transaction costs (3,647,818 shares at \$0.18 per share)	656,607
Total purchase price	\$4,706,061 =====

The fair value of the purchase price was valued at \$0.18 per share, which represented the closing price of the Company's stock at December 23, 2005. Acquisition related transaction costs include 3,647,818 shares issued to a financial advisor of ONX. The allocation of the purchase price to assets acquired and liabilities assumed is presented in the table that follows:

Tangible assets acquired	\$ 136,169
Property and equipment	29,772
Intangible assets	89,621
Goodwill	4,823,500
Other non-current assets	187,233
Liabilities assumed	(560,234)

Total purchase price	\$ 4,706,061 =====

The following summary, prepared on an unaudited pro forma basis, reflects the condensed consolidated results of operations for the three and six months ended

Edgar Filing: AcuNetx, Inc. - Form 10QSB

June 30, 2005 assuming OrthoNetx had been acquired at the beginning of the periods presented:

	Three Months ended June 30, 2005 -----	Six Months ended June 30, 2005 -----
Net revenue	\$ 402,785	\$ 723,694
Net loss	\$ (208,624)	\$ (529,419)
Basic and diluted net loss per share	\$ (0.00)	\$ (0.01)

PrivaComp, Inc.

On May 27, 2005, OrthoNetx, Inc. entered into an Agreement and Plan of Merger ("PrivaComp Agreement") with PrivaComp, Inc., a Delaware corporation that is in the business of developing technologies to provide patients with secure access to their medical records and control over their medical privacy. PrivaComp is considered a development stage company. The majority shareholder and CEO of PrivaComp is also the CEO and a shareholder/director of OrthoNetx. Under the terms of the PrivaComp Agreement, all of the issued and outstanding shares of PrivaComp stock were cancelled and converted into 1,000,000 shares of OrthoNetx's common stock.

OrthoNetx is the surviving corporation and assumed all assets and liabilities of PrivaComp, consisting primarily of developed software, a pending patent application and accounts payable. The merger was effective June 30, 2005.

PrivaComp and OrthoNetx are related through common ownership. Accordingly, the assets and liabilities of PrivaComp have been recorded by OrthoNetx at historical cost at June 30, 2005 as follows:

Assets:	
Intellectual Property	\$ 54,567
Liabilities:	
Accounts Payable	(62,669)

Net liabilities assumed	\$ (8,102)
	=====

PrivaComp had no activity during the three and six months ended June 30, 2005, therefore, no pro forma information has been presented.

13

NOTE 11 - MAJOR CUSTOMERS AND CREDIT CONCENTRATION

During the three months ended June 30, 2006, two customers accounted for \$342,235 or 94.2% of IntelliNetx division revenues. During the six months ended June 30, 2006, three customers accounted for \$609,590 or 94.3% of IntelliNetx division revenues.

National distributor	\$445,552 or 68.9%
Foreign distributor	\$67,173 or 10.4%
SID distributor	\$96,865 or 15.0%

During the three and six months ended June 30, 2005, the national distributor accounted for \$362,197 and \$616,950 or 89.92% and 85.72% of total revenues,

Edgar Filing: AcuNetx, Inc. - Form 10QSB

respectively.

The Company maintains cash deposits with major banks, which from time to time may exceed federally insured limits. The Company periodically assesses the financial condition of the institutions and believes that the risk of any loss is minimal.

NOTE 12 - SEGMENT INFORMATION

The Company evaluates its reporting segments in accordance with SFAS No. 131, "Disclosures about Segments of an Enterprise and Related Information." The Chief Executive Officer has been identified as the Chief Operating Decision Maker as defined by SFAS No. 131. The Chief Executive Officer allocates resources to each segment based on their business prospects, competitive factors, net sales and operating results.

In 2006, the Company changed the structure of its internally organization to develop three market-oriented operating divisions: (i) IntelliNetx (INX) division, (ii) OrthoNetx (ONX) division, and (iii) VisioNetx (VNX) division. The IntelliNetx division markets patented medical devices that assist in the diagnosis of dizziness and vertigo, and rehabilitate those in danger of falling as a result of balance disorders. The OrthoNetx division markets patented medical devices that mechanically induce new bone formation in patients with skeletal deformities of the face, skull, jaws, extremities and dentition. The VisioNetx division markets patented products that track and analyze human eye movements. The Company also has other subsidiaries that do not meet the quantitative thresholds of a reportable segment.

The Company reviews the operating companies' income to evaluate segment performance and allocate resources. Operating companies' income for the reportable segments excludes income taxes and amortization of goodwill. Provision for income taxes is centrally managed at the corporate level and, accordingly, such items are not presented by segment. The segments' accounting policies are the same as those described in the summary of significant accounting policies.

The Company does not track its assets by operating segments. Consequently, it is not practical to show assets by operating segments.

14

NOTE 12 - SEGMENT INFORMATION (CONTINUED)

Summarized financial information of the Company's results by operating segment is as follows:

	For Three Months ended June 30,		For Six Months June 30,	
	2006	2005	2006	
<hr/>				
IntelliNetx Division:				
Net revenue to external customers	\$ 363,130	\$ 402,785	\$ 646,705	\$
Cost of revenue	144,972	187,283	265,785	
	<hr/>		<hr/>	
Margin	\$ 218,158	\$ 215,502	\$ 380,920	\$

OrthoNetx Division:

Edgar Filing: AcuNetx, Inc. - Form 10QSB

Net revenue to external customers	\$	8,600	\$	--	\$	8,600	\$
Cost of revenue		3,703		--		3,703	
<hr/>							
Margin	\$	4,897	\$	--	\$	4,897	\$
<hr/>							
VisioNetx Division:							
Net revenue to external customers	\$	--	\$	--	\$	--	\$
Cost of revenue		--		--		--	
<hr/>							
Margin	\$	--	\$	--	\$	--	\$
<hr/>							
Total Net Revenue to External Customers	\$	371,730	\$	402,785	\$	655,305	\$
Total Cost of Revenue		148,675		187,283		269,488	
<hr/>							
Total Margin		223,055		215,502		385,817	
<hr/>							

Intersegment transactions are recorded at cost. The margins reported reflect only the direct controllable expenses of each line of business and do not represent the actual margins for each operating segment because they do not contain an allocation of product development, information technology, marketing and promotion, stock-based compensation, and corporate and general and administrative expenses incurred in support of the lines of business.

	For Three Months ended June 30,			
	2006	2005		

Total margin for reportable segments	\$ 223,055	\$ 215,502	\$	
Corporate and general and administrative expenses	(1,141,583)	(174,581)		(1
Stock option expenses	(136,846)	--		
Research and development	(146,022)	--		
Interest and Other Expense	(8,445)	(194)		
Loss on equity-method investments	(10,804)	--		
Interest and Other Income	11,021	128		

Net loss before income taxes	\$ (1,209,624)	\$ 40,855	\$	(2

15

NOTE 13 - COMMITMENTS

Sales Incentive Agreements

In April 2005, the Company entered into two individual agreements with the national distributor and a special instrument dealer. The agreements provide that the Company will issue restricted common stock to the distributor and dealer as a sale incentive if certain conditions are reached pursuant to the agreements. As of June 30, 2006, none of these conditions are reached and the Company issued no shares.

The sales incentive agreement with the national distributor was replaced by the Marketing and Distribution Agreement in May 2006.

Marketing and Distribution Agreement

Edgar Filing: AcuNetx, Inc. - Form 10QSB

On May 25, 2006 the Company executed a new Marketing and Distribution Agreement with the national distributor. The new agreement restructures the Company's relationship with the national distributor into a nonexclusive one, so that the Company will be in a position to manufacture and sell VNG products under its own brand names, as well as through the national distributor. The agreement also changes the relationship between the Company and the national distributor so that, in general, the Company will ship the national distributor branded products directly to the end-user, receive payment from the end-user, and pay the national distributor a commission on sales. The new Agreement is for a period of eight years, provides for successive three-year options, and supersedes and replaces the previous Manufacturing, Sales, Licensing, and Software Agreement and the Sales Incentive Agreement.

The Company also executed a Consulting Agreement with a consultant associated with the national distributor providing that the consultant agrees to provide advisory and consulting services to the Company for the purposes of improving the Company's VNG products and other balance-related product lines. The agreement is for a period of three years, and renews for an additional one-year term.

In return, the Company agreed to issue its common stocks worth \$100,000 on May 25, 2006 and an additional \$100,000 worth of common shares on each of the seven subsequent anniversaries of the signing date, which was May 25, 2006. The Company also agreed to pay the consultant \$1,500 per day with a minimum of 30 days per year. In July 2006, the Company had issued 444,445 shares of its common stocks to the national distributor for the first \$100,000 agreed payment.

NOTE 14 - GUARANTEES AND PRODUCT WARRANTIES

The Company from time to time enters into certain types of contracts that contingently require the Company to indemnify parties against third party claims. These contracts primarily relate to: (i) divestiture agreements, under which the Company may provide customary indemnifications to purchasers of the Company's businesses or assets; (ii) certain real estate leases, under which the Company may be required to indemnify property owners for environmental and other liabilities, and other claims arising from the Company's use of the applicable premises; and (iii) certain agreements with the Company's officers, directors and employees, under which the Company may be required to indemnify such persons for liabilities arising out of their employment relationship.

The terms of such obligations vary. Generally, a maximum obligation is not explicitly stated. Because the obligated amounts of these types of agreements often are not explicitly stated, the overall maximum amount of the obligations cannot be reasonably estimated. Historically, the Company has not been obligated to make significant payments for these obligations, and no liabilities have been recorded for these obligations on its balance sheet as of June 30, 2006.

In general, the Company offers a one-year warranty for most of the products it sold. To date, the Company has not incurred any material costs associated with these warranties. The Company provides reserves for the estimated costs of product warranties based on its historical experience of known product failure rates, use of materials to repair or replace defective products and service delivery costs incurred in correcting product failures. In addition, from time to time, specific warranty accruals may be made if unforeseen technical problems arise with specific products. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary

Edgar Filing: AcuNetx, Inc. - Form 10QSB

NOTE 14 - GUARANTEES AND PRODUCT WARRANTIES (CONTINUED)

The following table presents the changes in the Company's warranty reserve during the first six months of 2006 and 2005:

	2006	2005
	-----	-----
Balance as of beginning of period	\$ 8,462	\$ 8,884
Provision for warranty	1,051	1,748
Utilization of reserve	(1,051)	(3,174)
	-----	-----
Balance as of end of period	\$ 8,462	\$ 7,458
	=====	=====

NOTE 15 - DEPARTURE AND ELECTION OF CHAIRMAN OF THE BOARD OF DIRECTORS

On May 2, 2006, Stephen D. Moses resigned from the Board of Directors of Registrant and as Chairman of the Board of Directors. The resignation arose out of disagreements about the management and direction of the Company. The remaining Directors of the Company disagree with the assertions of Mr. Moses.

On May 3, 2006, Charles Phillips, the Company's co-founder in 1988 and currently a Director, was elected as the Chairman of the Board of Directors of the Company.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION BUSINESS OVERVIEW

AcuNetx is organized around three separate divisions: (i) a division that produces neurological diagnostic equipment, (ii) a division that produces devices that create new bone, and (iii) a division that develops products for occupational safety and law enforcement. For all its devices, AcuNetx is integrating an information technology (IT) platform that allows the device to capture data about the physiological condition of a human being. Our IT platform is designed to gather data and connect the device-related data with users and support persons. The Company's products include the following:

- o Neurological diagnostic equipment that measures, tracks and records human eye movements, utilizing our proprietary technology and computer software, as a method to diagnose problems of the vestibular (balance) system and other balance disorders.
- o Devices designed to test individuals for impaired performance resulting from the influences of alcohol, drugs, illness, stress and other factors that affect eye and pupil performance. These products target the occupational safety and law enforcement markets.
- o Orthopedic and craniomaxillofacial (skull and jaw) surgery products, which generate new bone through the process of distraction osteogenesis.
- o A proprietary information technology system called SmartDevice-Connect(TM) ("SDC") that establishes product registry to individual patients and tracks device behavior for post-market surveillance, adverse event and outcomes reporting, and creates "smart devices" that gather and transmit physiological data concerning the device and its interaction with the patient.

RESULTS OF OPERATIONS

THREE MONTHS ENDING JUNE 30, 2006 COMPARED TO THREE MONTHS ENDED JUNE 30, 2005

As described above, AcuNetx, Inc. is comprised of the former Eye Dynamics, Inc. and the former OrthoNetx, Inc. This discussion compares the combined 2006 second quarter and first half results with the corresponding periods of 2005, which consists solely of the former Eye Dynamics, Inc.

In May of 2006, negotiations successfully concluded with our national distributor for IntelliNetx (formerly Eye Dynamics) products. The revised contract allows exclusivity for that distributor for the Company's products they have traditionally sold, while allowing new IntelliNetx lines to be sold through a broader range of channels and partners. One significant aspect of the new contract is a shift in revenue recognition. Prior to the revised contract, IntelliNetx products would be considered purchased by the distributor and revenue would be credited at the previously agreed upon wholesale price. Under the now revised contract, shipments and title to the equipment move directly from IntelliNetx to the end customer, and IntelliNetx recognizes the revenue at the retail price. This change will result in higher revenues for the same unit volume of sales, along with higher gross profits, as costs will not change. An offsetting increase in selling expenses occurs as the distributor is paid from the retail proceeds. The functional implementation of the changes to our distribution agreement occurred at the end of this quarter. Material results associated with this change will be reflected from this point forward.

Revenues during the second quarter of 2006 were \$371,730, compared to \$402,785 for the corresponding period in 2005. Unit shipments were down modestly from the prior year, which was slightly offset by 2 systems being booked at the retail level as described above. Unit cost of sales stayed relatively static, while gross profit, as a percentage of sales increased 6.5%, again due to the shift to retail.

Total operating expenses increased by \$1,249,870 from \$174,581 in the second quarter of 2005 to \$1,424,451 in the second quarter of 2006. Increased selling, general and administrative expenses resulted in a loss of \$1,209,624 (\$0.02 per share) for the current period, compared to a profit of \$39,579 (\$0.00 per share) for the same period in the previous year. Unit sales did not show the budgeted growth hoped for in the second quarter as lengthy negotiations with our distributor diverted sales efforts. As stated above, a satisfactory conclusion to those discussions occurred near the end of the quarter and is expected to bring sales through that channel back to prior year levels or better. We are working with all of our marketing channels to formulate a consistent message to highlight our product and company strengths. Sales for the OrthoNetx line of products continue at a very slow pace while the correct distribution model is sought. Most of the loss in the quarter was driven by the increase in operating expenses discussed in the 6 month results below.

SIX MONTHS ENDED JUNE 30, 2006 COMPARED TO SIX MONTHS ENDED JUNE 30, 2005

Revenues during the first six months of 2006 were \$655,305, compared to \$719,694 for the corresponding period in 2005. Unit shipments were down modestly from the prior year, with a slight offset for 2 units sold at retail. Unit cost of sales stayed relatively static, while gross profit, as a percentage of sales increased 4.3%, again due to the shift to retail revenue booking near the end of the period.

Total operating expenses increased by \$1,990,361, from \$415,355 in the first half of 2005 to \$2,405,716 in the first half of 2006. Substantial new product development expenses as well as increased selling, general and administrative expenses resulted in a loss of \$2,052,154 (\$0.04 per share) for the current period, compared to a loss of \$35,881 (\$0.00 per share) for the same period in the previous year.

The company directed significant expenditures in the first six months of combined operations for design work on the SafetyScan product which was completed through phase I. The HawkEye product for law enforcement use was further developed and brought to market, and is generating substantial interest. Improvements of form and function in the current VNG product line were also undertaken. We finalized the administrative, legal, and regulatory aspects of the merger so to build the base for future growth. These changes included a new accounting system, an I/T infrastructure compliant with regulatory requirements, and able to expand in support of the future SmartDevice-Connect backbone, a re-designed web site that meets current standards and will support e-commerce, patent and trademark filings, and the rollout of an improved branding, positioning, and market image for the company. Standard selling, general and administrative expenses for both AcuNetx and OrthoNetx did not increase significantly, but the OrthoNetx expenses make up a portion of the year to year growth. The shift to recognizing revenue at the retail level for IntelliNetx products mentioned earlier will result in an increase in selling expense which offsets the higher gross profit for units sold through our national distributor, and will return higher contributions to net income for units sold through new channels. The effect of this change was minimal in this period.

LIQUIDITY AND CAPITAL RESOURCES

Cash and cash equivalents as of June 30, 2006 of \$99,491 will not allow for payment of all outstanding invoices on a current basis. All suppliers to the revenue generating operations of IntelliNetx are current, and can remain so with current cash and sales. Creditors have been kept informed of the financial situation of the Company, and both work and payment plans are being established. The Company is also in the process of repaying a loan from the founder of OrthoNetx, and is current on interest as of June 30, but is a month behind on principal payment.

Inventory as of June 30, 2006 was \$340,160, compared to \$264,000 as of June 30, 2005. Purchasing for all VNG products has been adjusted to a level consistent with lower sales. OrthoNetx bone distraction products, both the GenerOs CF and GenerOs SB, account for most of the overall increase year to year. Accounts receivable as of June 30, 2006 were \$124,408. A dedicated push in July reduced this number substantially, and new programs have been instituted to prevent A/R delinquencies reaching that level in the future.

Accounts payable as of June 30, 2006 were \$401,147, compared to \$39,898 as of June 30, 2005. The change is primarily due to significant increases in activity as reflected in the combined companies' selling, general and administrative expense discussed above. OrthoNetx had previously acquired a private firm, and has been carrying accounts payable at full value until a settlement, currently under discussion, is resolved.

Sales prospects for the balance of 2006 continue to appear strong, as we operate under a new contract with our current distributor and introduce new and refreshed products through new channels and sales partners. We also expect that sales of our HawkEye product to the law enforcement community will begin to be

Edgar Filing: AcuNetx, Inc. - Form 10QSB

reflected beginning in the third quarter this year. In early April we announced that our VNG products have been approved by the U. S. Government Services Administration to be listed on the Federal Supply Schedule, which permits access to all military and VA hospitals around the world. We plan to continue to use trade shows, print and electronic media, industry experts, and distributors to carry our message to our expanding base of customers and support organizations.

Finally, the Company has embarked on an effort to raise additional capital (approximately \$4 million) to complete the development of its SafetyScan product, to introduce it to the marketplace, and to fund marketing and sales efforts aimed at increasing revenues associated with the Company's other product lines.

19

ITEM 3. CONTROLS AND PROCEDURES.

At the end of the period covered by this Form 10-QSB, the Company's management, including the Chief Executive and Chief Financial Officers, conducted an evaluation of the effectiveness of the Company's disclosure controls and procedures. Based on this evaluation, the Chief Executive and Chief Financial Officers have determined that such controls and procedures are effective to ensure that information relating to the Company required to be disclosed in reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. There have been no changes in the Company's internal controls over financial reporting that were identified during the evaluation that occurred during the Company's last fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company is not a party to any material pending legal proceedings.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None

ITEM 5. OTHER INFORMATION

None

ITEM 6. EXHIBITS

31.1 Certification of the Company's Chief Executive Officer
Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities

Edgar Filing: AcuNetx, Inc. - Form 10QSB

Exchange Act of 1934

- 31.2 Certification of the Company's Interim Chief Financial Officer Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934
- 32.1 Certification of the Company's Chief Executive Officer Pursuant to 18 U.S.C. Section 1350
- 32.2 Certification of the Company's Interim Chief Financial Officer Pursuant to 18 U.S.C. Section 1350

20

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 21, 2006

By: /s/ Terry Knapp

Terry Knapp, President

21